Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ism Biosciences LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. The presence of 1 distinct art unit indicates that the company's current pharmaceutical filing is categorized within a specific technical group at the patent office. This focused interaction suggests that the company's immediate prosecution efforts are concentrated in a single area of expertise within the biotechnology sector.
Leon B Lankford Jr is the busiest examiner for the company with 1 pending office action. As this is the only pending office action for the portfolio, this examiner manages the full scope of the company's current prosecution activity. The busiest examiner pending count of 1 confirms that the entire workload is centered on this individual. With only 1 distinct examiner and 1 distinct art unit involved, the company's success in this matter depends on navigating the specific requirements and review style of Leon B Lankford Jr. Practitioners should focus their efforts on the historical tendencies of this examiner to effectively manage the 1 pending office action currently active for Ism Biosciences LLC.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18739957 | PHARMACEUTICAL COMPOSITION AND METHODS FOR MODULATING INFLAMMATION AND OXIDATIVE STRESS | LANKFORD JR, LEON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18739957 | PHARMACEUTICAL COMPOSITION AND METHODS FOR MODULATING INFLAMMATION AND OXIDATIVE STRESS | LANKFORD JR, LEON B | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18739957 | PHARMACEUTICAL COMPOSITION AND METHODS FOR MODULATING INFLAMMATION AND OXIDATIVE STRESS | LANKFORD JR, LEON B | 1657 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIsm Biosciences LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Leon B Lankford Jr. has the most, with 1 of Ism Biosciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
